Neovasc (NVCN) PT Lowered to $2 at Leerink Partners; 'Tiara Clinical Trials Continue to Progress'

March 29, 2018 3:07 AM EDT
Get Alerts NVCN Hot Sheet
Price: $0.95 --0%

Rating Summary:
    5 Buy, 1 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 17 | New: 52
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Leerink Partners lowered its price target on Neovasc (NASDAQ: NVCN) to $2.00 (from $5.00) while maintaining a Outperform rating.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst PT Change